Navigation Links
Axikin Pharmaceuticals Spins out of Actimis
Date:1/22/2009

SAN DIEGO, Jan. 22 /PRNewswire/ -- Axikin Pharmaceuticals, Inc., a startup company dedicated to developing and commercializing small molecule therapeutics for respiratory and inflammatory diseases, today announced a $3 million private placement of its Series A stock. The financing was led by Sanderling Ventures of San Mateo, California. Additional investors include Mitsui & Co. Venture Partners of New York.

Axikin Pharmaceuticals, Inc., was formed as a spin-out from Actimis Pharmaceuticals, Inc., (www.actimis.com) following the acquisition of Actimis' lead program by Boehringer Ingelheim in a structured buyout in June 2008. Axikin's pipeline includes an advanced pre-clinical program with multiple highly optimized small-molecule lead candidates, as well as two additional novel target research programs. These programs are expected to have broad applications across respiratory and allergic diseases including asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD) with, potentially, broader applications in inflammation, autoimmunity, oncology and cardiovascular disease.

"The establishment of Axikin Pharmaceuticals, Inc., and the additional funding we have received to progress these assets, allows us to hit the ground running and provide significant continuity in the quest to bring our lead candidates to the clinic," said Kevin B. Bacon, Ph.D., founder, President and Chief Scientific Officer of Axikin, and original founder of Actimis. "Building on our excellent relationship with our prior investor partners, and retaining the same team of highly-dedicated scientists greatly facilitates our goal of filing an investigational new drug application (IND) for our lead program in the very near future."

"The investors are delighted to be backing the same proven team again in this new spin-out Company," said Peter C. M. McWilliams, Ph.D., Chairm
'/>"/>

SOURCE Axikin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... The Minnesota High Tech Association ... cellular modems , platforms and application-specific remote monitoring ... for the 2014 Tekne Awards. The awards ... Convention Center on Thursday, November 13th. The Tekne ... shown superior technology innovation and leadership. , ...
(Date:9/22/2014)... Pearl's Premium Ultra Low Maintenance Lawn Seed ... seed this week with the release of their Pearl's ... the fact that it is time to plant now ... , As of the date 6/4/13, Pearl's Premium had ... experts and the media including: The National Gardeners ...
(Date:9/22/2014)... Thanks to new LEGO-like components developed by researchers ... is now possible to build a 3-D microfluidic ... small modules by hand. , Microfluidic systems ... and biotechnology to precisely manipulate small volumes of ... or DNA analysis, pathogen detection, clinical diagnostic testing, ...
(Date:9/22/2014)... a new star-shaped molecule made up of interlocking rings, which ... , Known as a ,Star of David, molecule, scientists ... of a century and the team,s findings are published in ... two molecular triangles, entwined about each other three times into ... triangle is 114 atoms in length around the perimeter. The ...
Breaking Biology Technology:NimbeLink Named Finalist for 15th Annual Tekne Awards 2NimbeLink Named Finalist for 15th Annual Tekne Awards 3Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5
... Finger Nuclease Platform enables Precise, Permanent, and ... Heritable Modification of the Genome, ... CompoZr(TM) platform of zinc finger nuclease (ZFN),reagents. The CompoZr ZFN ... to target and precisely manipulate the genome,of living cells, resulting ...
... plant-based extract, is better than metformin, the leading Type 2 diabetes ... ... Winter Haven, FL (PRWEB) September 16, 2008 -- A ... 2 diabetics better than a leading prescription drug, according to the ...
... Development of Gene Expression Signatures Derived by COXEN ... Molecular Test of Responsiveness to Current Treatments, ... Transgenomic (OTC Bulletin Board: TBIO) today announced a ... test which will guide,clinicians in their choice of ...
Cached Biology Technology:Sigma-Aldrich Launches Breakthrough Genome-Editing Tools 2Sigma-Aldrich Launches Breakthrough Genome-Editing Tools 3Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™ 2Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options 2Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options 3Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options 4
(Date:9/21/2014)... (black-eyed peas) is a fascinating example of how science ... the story of the scientist behind the research. ... the 21st Century to serve as an accessible summary ... recently published by the Crop Science Society of America, ... , Singh has devoted his life,s work to solving ...
(Date:9/21/2014)... MA -- In recent years, new strains of bacteria ... Each year, these superbugs, including drug-resistant forms of tuberculosis ... and kill at least 23,000. Despite the urgent need ... classes of antibiotics in the past decade. , MIT ... these superbugs. Using a gene-editing system that can disable ...
(Date:9/21/2014)... a protein therapy that disrupts the process that causes ... travel through the blood stream and start aggressive new ... as metastasis, can cause cancer to spread with deadly ... to cancer fall prey to metastatic forms of the ... who describes a new therapeutic approach in Nature ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... long puzzled scientists, and several scenarios have been proposed ... group appeared virtually simultaneously on Asia, Europe and North ... new research using the latest evidence suggests a completely ... that sudden, rapid global warming drove the dispersal. ...
... Researchers at the Burnham Institute for Medical Research have ... free radicals and accumulation of misfolded proteins that lead ... such as Alzheimer's and Parkinson's Disease. , ... protein that is necessary for proper protein folding in ...
... The study of 18 HIV-positive subjects shows that HIV in ... HIV that lives in the blood and peripheral tissues. , ... with the presence of a particular mutation in the HIV ... 2006 issue of Brain. It was led by Satish K. ...
Cached Biology News:Ancient global warming drove early primates' dispersal 2Key stress protein linked to toxicities responsible for Parkinson's, Alzheimer's 2Viral genetic differences are possible key to HIV dementia 2Viral genetic differences are possible key to HIV dementia 3
... is proud to work in collaboration with ... 25mm syringe filters in a variety of ... licensed for use on the Caliper TPWII, ... and Pricing for our Automation Certified Syringe ...
... 3 Dodeca cell with multi-casting chamber is used ... 12 mini format handcast (8.3 x 7.3 cm) ... cell requires 3.4-4.4 L of buffer and includes ... attaches to an external refrigerated circulator (not included), ...
...
... This product has been developed to ... peroxidase labeled proteins. Stability is increased ... to 2-8 centigrade. This product is ... no mercury or azide. This formulation ...
Biology Products: